20 Hampden Street
Boston, MA 02119
Phone: 617-442-8628

Carl Weissman, chief operating officer
Privately Held


Centagenetix Inc. was founded in May 2001 to discover the genetics of longevity and apply the findings to the development of treatments for age-related illnesses, including Alzheimer’s disease, cardiovascular disease and certain types of cancer.

Centagenetix uses its database of genetic and phenotypic information from centenarians for comparison in the discovery, identification and study of specific genes associated with age-related diseases. Centagenetix is studying centenarians, people who live past 100.

The company has plans to enlarge its Ideal Genome database, which will contain data on studies of specific genes that affect age-related diseases. The company, which currently has four employees, has plans to build out a complete team in R&D, research study recruitment, administration and management.

In August 2001, the researchers who founded Centagenetix said they discovered a specific region of chromosome 4 in humans in which it is likely that a gene or genes exist associated with extraordinary longevity.


The company had not formed any notable partnerships.